About the Authors
- Fiona Maas
-
* E-mail: f.maas@umcg.nl
Affiliation Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- Suzanne Arends
-
Affiliations Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, Rheumatology, Medical Center Leeuwarden, Leeuwarden, The Netherlands
- Freke R. Wink
-
Affiliation Rheumatology, Medical Center Leeuwarden, Leeuwarden, The Netherlands
- Reinhard Bos
-
Affiliation Rheumatology, Medical Center Leeuwarden, Leeuwarden, The Netherlands
- Hendrika Bootsma
-
Affiliation Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- Elisabeth Brouwer
-
Affiliation Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- Anneke Spoorenberg
-
Affiliations Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, Rheumatology, Medical Center Leeuwarden, Leeuwarden, The Netherlands
Competing Interests
F. Maas: None declared; S. Arends: Grant/research support from Pfizer; F.R. Wink consultant for Abbvie; R. Bos: None declared; H. Bootsma: None declared; E. Brouwer: Grant/research support from Pfizer; A. Spoorenberg: Grant/research support from Abbvie, Pfizer, UCB, consultant for Abbvie, Pfizer, MSD, UCB, and Novartis. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: AS SA EB HB. Data curation: AS FRW RB EB. Formal analysis: FM. Funding acquisition: AS SA. Investigation: FM AS SA. Methodology: FM AS SA. Project administration: AS SA HB. Resources: FM AS FRW RB EB. Supervision: AS SA HB. Validation: SA. Visualization: FM. Writing – original draft: FM.